Silexion Therapeutics ( $SLXN ): Why Reclaiming the $1.00 Level Remains a Key Focus (Check any stock’s price target on Tickeron.) The selected price target is $1.00, a psychological milestone and the level typically required to satisfy Nasdaq's minimum bid price listing rule. Silexion is a clinical-stage biotech advancing SIL204, an RNA interference (RNAi) therapy for KRAS-driven pancreatic cancer, with a Phase 2/3 trial approved in Israel and Germany. $IMA $CELC $CDT $INKT $ENSC
published
Silexion Therapeutics ( $SLXN ): Why Reclaiming the $1.00 Level Remains a Key Focus (Check any stock’s price target on Tickeron.) The selected price target is $1.00, a psychological milestone and the level typically required to satisfy Nasdaq's minimum bid pri
$SLXN$IMA$CELC$CDT$INKT$ENSC
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.